PHS
GALT icon

Pekin Hardy Strauss’s Galectin Therapeutics GALT Stock Holding History

Pekin Hardy Strauss’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$139K Hold
30,000
– – 0.01% 487
2026
Q1 		$83.7K Buy
+30,000
New +$91.3K 0.01% 461

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Pekin Hardy Strauss's GALT Position: Q2 2026 in Review

Pekin Hardy Strauss held its Galectin Therapeutics (GALT) position steady in Q2 2026 at 30,000 shares worth $139K. The position accounts for 0.01% of the portfolio, ranked #487.

Pekin Hardy Strauss first reported a position in GALT in Q1 2026 and has held it in 2 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Pekin Hardy Strauss held 30,000 shares of Galectin Therapeutics worth $139K as of Q2 2026.
  • Pekin Hardy Strauss left its Galectin Therapeutics share count unchanged in Q2 2026.
  • Galectin Therapeutics made up 0.01% of Pekin Hardy Strauss's portfolio in Q2 2026, its #487 holding.
  • Pekin Hardy Strauss first reported a position in Galectin Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Pekin Hardy Strauss's 13F filing for Q2 2026, filed 30 Jul 2026.